Results 101 to 110 of about 72,674 (159)

Target Attainment and Clinical and Biochemical Parameters Associated with the Pharmacokinetics of 12 Tyrosine Kinase Inhibitors. [PDF]

open access: yesClin Pharmacokinet
Shirity ZNA   +9 more
europepmc   +1 more source

CML Chapter

2021
The discovery of the tyrosine kinase inhibitor (TKI) imatinib in the early 2000's revolutionized the treatment and prognosis of patients with chronic myeloid leukemia (CML) [Hochhaus et al. in N Engl J Med 376:917-927, 2017]. The treatment of patients with CML has changed dramatically since the approval of imatinib and other TKIs.
openaire   +2 more sources

Treatment of CML in pregnancy

Hematology, 2022
Abstract Since the introduction of tyrosine kinase inhibitors (TKIs) at the beginning of the millennium, the outlook for patients with chronic myeloid leukemia (CML) has improved remarkably. As such, the question of life expectancy and survival has become less problematic while quality of life and family planning have become more so ...
Harry F, Robertson, Jane F, Apperley
openaire   +2 more sources

Home - About - Disclaimer - Privacy